Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Subscribe To Our Newsletter & Stay Updated
